Posted on

The Unites States Drug Enforcement Administration claims that it intends to make a final decision on whether or not to reclassify marijuana sometime during the first half of this year, as reported by The Huffington Post.

According to the Weed Blog, a group of Senators issued a letter late last year insisting that the DEA to research and take action on rescheduling marijuana. In a letter dated April 4, the DEA responded to the Senators. Per the Huffington Post:

DEA will carry out its assessment of the FDA recommendation in accordance with the CSA requirements … Once a final determination has been made, DEA will notify petitioners. DEA understands the widespread interest in the prompt resolution of these petitions and hopes to release its determination in the first half of 2016.

Advocates and major supporters have been fighting for reclassification concerning marijuana for years,.Sun Times Network cited that even influential politicians like  presidential candidate Hillary Clinton is showing support for reclassifying cannabis to promote further medical research.

“Despite unique restrictions on conducting marijuana research, a plethora of scientific evidence has nevertheless emerged that not only confirms marijuana’s medicinal benefits but also its wide margin of safety,” according to the Drug Policy Alliance. “Yet because of marijuana’s Schedule I designation, physicians cannot prescribe it and instead can only recommend its use without legal access or protection for their patients.”

Although the DEA’s letter, which is signed by acting Administrator Chuck Rosenberg, does not specifically speak on the certainty of a Schedule reclassification, there is an increasing amount of push for the agency to provide an agreeable outcome concerning the issue.

As told by High Times, the letter states that the agency will highly consider the most recent discoveries from the U.S. Food and Drug Administration deriving from the agency’s eight-factor analysis of the medical and scientific evidence supporting cannabis as a safe and effective drug. But the DEA made no mention as to whether the FDA review was in favor or against rescheduling.

(Photo Courtesy of